Effects of Tyrosine Kinase Inhibitors on Liver Enzymes and Electrolytes

Assiut University40 enrolled

Overview

Determine the effects of tyrosine kinase Inhibitors on liver enzymes and electrolytes in relation to hematologic response in patients with chronic phase chronic meyloid leukemia.. Assiut University Hospital insight..

CML is a myeloproliferative neoplasm with unique biological and clinical features. CML accounts for 15\_20% of newly diagnosed cases of leukemias among adults. CML can present in three clinical phases : chronic phase, accelerated phase and blast phase. CML is characterized by prodction of a breakpoint cluster region abelson(BCR-ABL) fusion protein with ABL kinase activity. This is due to reciprocal translocation between chromosome 9 and 22. Imatinib \& Nilotinib, an ABL kinase inhibitors, which has revolutionized the CML therapy, are a selective tyrosine kinase inhibitors. The aim of the study is to determine the changes of liver enzymes and electrolytes in relation to hematologic response during treatment period.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Patients Diagnosed as Chronic Meyloid Leukemia

Interventions

Tyrosine kinase Inhibitors (Imatinib & Nilotinib)DRUG

Administration of tyrosine kinase inhibitors (Imatinib in a dose of 400mg/day \& Nilotinib in adose of 600mg/day)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Newly diagnosed patients with CML * Chronic phase CML * Normal hepatic and renal functions Exclusion Criteria: * Blastic phase CML * Accelerated phase CML * Hepatic \& renal impairment

Locations (1)

Assiut University Hospital

Asyut, Egypt

Outcomes

Primary Outcomes

Follow up liver enzymes as AST, ALT, ALP and GGT before starting treatment and during the period of treatment by Tyrosine Kinase Inhibitors (Imatinib & Nilotinib).

Changes happen in liver enzymes after a period of treatment by Tyrosine Kinase Inhibitors (Imatinib \& Nilotinib) which are assessed by measuring liver enzymes as AST, ALT, ALP, GGT before starting treatment and during the period of treatment and the relation between these changes and the hematologic response to the treatment that is assessed by CBC and BCR-ABL Gene.

Time frame: 6 months

Follow up electrolytes as Na, K, Ca and P before starting treatment and during the period of treatment by Tyrosine Kinase Inhibitors (Imatinib & Nilotinib)

Changes happen in electrolytes after a period of treatment by Tyrosine Kinase Inhibitors (Imatinib \& Nilotinib) which are assessed by measuring electrolytes levels before starting treatment and during the period of treatment and the relation between these changes and the hematologic response to the treatment that is assessed by CBC and BCR-ABL Gene

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.